NCT05421013已完成1 期
An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Subjects With Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
Sirnaomics1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2022年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Proportion of participants with histological clerance of treated isSCC lesion at the end of treatment
研究概览
简要总结
Open label, dose escalation to evaluate safety.
详细描述
Evaluate safety, tolerability, and efficacy of various doses of STP705 administered as intralesional injection in subjects with facial isSCC.
There will be 3 cohorts of 10 subjects each. Enrolled subjects will receive STP705 once weekly for 6 weeks. The lesion will be excised 60 days after.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects are required to meet all of the following criteria for enrollment into the study:
- •Male or female adult ≥ 18 years of age.
- •Primary, histologically confirmed facial isSCC lesion suitable for excision with a minimum diameter of 0.5 cm and with a maximum diameter of 2.0 cm.
- •Histological diagnosis of a qualified isSCC skin lesion (evidenced by a confirmatory histopathology report) made no more than 6 months prior to the screening visit.
- •No other dermatological disease in the isSCC target lesion or surrounding area, which in the opinion of the investigator, could interfere with the study.
- •Willing to refrain from using non-approved lotions or creams on the target lesion and surrounding area during the treatment period (sunscreen and moisturizers allowed).
- •Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.
- •Laboratory values for the tests (listed in the Study Schedule) within the reference ranges as defined by the local laboratory, or "out of range" test results that are clinically acceptable to the investigator.
- •Ability to follow study instructions and likely to complete all study requirements.
- •Written informed consent obtained, including consent for tissue to be examined and stored by the Central Histology Lab.
- •Written consent to allow photographs of the target isSCC lesion to be used as part of the study data and documentation.
- •For female subjects of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral / implantable / injectable / transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy at least 6 months prior to screening).
- •EXCLUSION CRITERIA
- •Pregnant, lactating, or planning to become pregnant.
- •Presence of known or suspected systemic cancer.
- •Confirmatory histological report of the qualified isSCC lesion reveals evidence of severe squamous metaplasia, infiltrative, desmoplastic or micronodular growth patterns in the opinion of the investigator.
- •History of recurrence of the target isSCC lesion.
- •Concurrent disease or treatment that suppresses the immune system.
- •Subjects with baseline QT corrected interval QTc > 480 msec using Fridericia's formula.
- •Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk.
- •Known sensitivity to any of the ingredients in the study medication including an allergy to trehalose.
- •Use of a tanning bed or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the study.
- •Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit.
- •Use of systemic retinoids within the 6 months prior to the screening period.
- •Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period.
- •Use of topical immunomodulators within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening period.
- •Treatment with the following topical agents within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening visit: aminolevulinic acid, 5-fluorouracil, corticosteroids, retinoids, diclofenac, ingenol mebutate, tirbanibulin, or imiquimod.
- •Treatment with liquid nitrogen, surgical excision, or curettage within 2 cm of the target isSCC lesion during the 4 weeks prior to the screening visit.
- •Evidence of current chronic alcohol or drug abuse that, in the opinion of the investigator, would impair the subject's ability to comply with study schedule.
- •Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit.
- •In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.
排除标准
- 未提供
研究组 & 干预措施
STP705 30ug
Experimental
STP705 will be administered once weekly for 6 weeks
干预措施: STP705 (Drug)
STP705 60ug
Experimental
STP705 will be administered once weekly for 6 weeks
干预措施: STP705 (Drug)
STP705 90ug
Experimental
STP705 will be administered once weekly for 6 weeks
干预措施: STP705 (Drug)
结局指标
主要结局
Proportion of participants with histological clerance of treated isSCC lesion at the end of treatment
时间窗: 21 weeks
Histological clearance will be defined as the absence of detectable evidence of isSCC tumor cell nests determined by pathology review
次要结局
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)(21 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid TumorsSolid TumorNCT05037149Sirnaomics50
撤回
1 期
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS IIMucopolysaccharidosis IINCT05238324Homology Medicines, Inc
撤回
1 期
An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL AmyloidosisLight Chain (AL) AmyloidosisNCT05692908Sorrento Therapeutics, Inc.
已完成
2 期
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell CarcinomaBasal Cell CarcinomaNCT04669808Sirnaomics32
已完成
1 期
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard TherapyLiver MetastasesHepatocellular CarcinomaCholangiocarcinomaNCT04676633Sirnaomics5